1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Ibogaine: A Review (2001)

Ibogaine: A Review (2001)

  1. Jatelka
    Alkaloids Chem Biol. 2001;56:1-38

    Alper

    Ibogaine, a naturally occurring plant alkaloid with a history of use as a medicinal and ceremonial agent in West Central Africa, has been alleged to be effective in the treatment of drug abuse. The National Institute on Drug Abuse (NIDA) has given significant support to animal research, and the U.S. Food and Drug Administration (FDA) has approved Phase I studies in humans. Evidence for ibogaine’s effectiveness includes a substantial preclinical literature on reduced drug self-administration and withdrawal in animals, and case reports in humans. There is relatively little financial incentive for its development by the pharmaceutical industry because ibogaine is isolated from a botanical source in which it naturally occurs, and its chemical structure cannot be patented. This has left the academic community and the public sector with a crucial role in research on ibogaine, which was a major reason for organizing the First International Conference on Ibogaine.
    A major focus of the Conference was the possible mechanism(s) of action of ibogaine. Ibogaine is of interest because it appears to have a novel mechanism of action distinct from other existing pharmacotherapeutic approaches to addiction, and it potentially could provide a paradigm for understanding the neurobiology of addiction and the development of new treatments. Another important focus of the Conference was to review human experience with ibogaine and preclinical and clinical evidence of efficacy and safety. The Conference also featured presen-tations related to the sociological and anthropological aspects of the sacramental context of the use of iboga in Africa and the distinctive ibogaine subculture of the United States and Europe.